MedTrace Logo

Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)

NCT01163942 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to examine the effect of G-CSF on disease free survival and overall survival in aplastic anaemia patients who also receive ATG and Cyclosporin A.

Conditions

  • Aplastic Anaemia

Interventions

DRUG

G-CSF

Yes/no addition of G-CSF

DRUG

Early retreatment with ATG

Yes/no early retreatment with ATG

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • European Society for Blood and Marrow Transplantation

    lead NETWORK

Principal Investigators

  • André Tichelli, Prof. MD. · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2008-06-30
Completion
2010-11-30

Countries

  • Czechia
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01163942 on ClinicalTrials.gov